health
RBC/Hemoglobin Decrease
Adverse effectRBC/Hemoglobin Decrease means a reduction in red blood cells or hemoglobin, the blood components measured when assessing oxygen-carrying capacity. It may be described as anemia when the decrease in hemoglobin is clinically interpreted that way.
Explore RBC/Hemoglobin Decrease as a health-related effect.
These are research findings, not promises. Most options have little evidence, and results differ from person to person.
What can cause it
How likely each one is to cause it, most likely first.
Ozone TherapypracticeUnclear
Based on 2 studies. Strongest study: a systematic review of studies.
A 2026 systematic review pooling randomized and non-randomized human studies reported hemolysis. The finding does not specify how often it occurred or in whom.
Open the Ozone Therapy pageIV Vitamin DrippracticeUnclear
Based on one study. Strongest study: a single case report.
A case report involving a person with hyperlipidemia, hypothyroidism, and kidney disease described red cell lysis and capillary leak, which were thought to trigger systemic inflammation, vascular collapse, and metabolic derangement.
Open the IV Vitamin Drip pageCupping TherapypracticeUnclear
Based on one study.
A pharmacology reference notes that repeated or excessive wet cupping can cause blood-loss anemia.
Open the Cupping Therapy pageFastingpracticeUnclear
Based on one study. Strongest study: an animal study.
A 2026 study in animals found elevated red cell distribution width, described as an erythropoietic stress pattern and a possible mild anemia-like phenotype. This animal finding does not establish the same effect in people.
Open the Fasting page
The expert view shows every study, dose protocol and source.
What can cause it
Interventions reported to bring this on4 listedHighest probability
- →PracticesOzone TherapyCertaintyLowSourceClinical2 other sources
A 2026 systematic review pooling randomized and non-randomized human studies reported hemolysis. The finding does not specify how often it occurred or in whom.
- →PracticesIV Vitamin DripCertaintyLowSourceClinical1 other source
A case report involving a person with hyperlipidemia, hypothyroidism, and kidney disease described red cell lysis and capillary leak, which were thought to trigger systemic inflammation, vascular collapse, and metabolic derangement.
Who was studied
- People with a condition
- Hyperlipidemia
- Hypothyroidism
- Kidney Disease
Open IV Vitamin DripStudy result
The red cell lysis and capillary leak that followed likely triggered systemic inflammation, vascular collapse, and metabolic derangement.
- →PracticesCupping TherapyCertaintyLowSourceReference knowledge1 other source
A pharmacology reference notes that repeated or excessive wet cupping can cause blood-loss anemia.
Open Cupping TherapyStudy result
Repeated or excessive wet cupping can cause blood-loss anemia.
- →PracticesFastingCertaintyLowSourceAnimal research1 other source
A 2026 study in animals found elevated red cell distribution width, described as an erythropoietic stress pattern and a possible mild anemia-like phenotype. This animal finding does not establish the same effect in people.
Who was studied
- Healthy people
Open FastingStudy result
Elevated red cell distribution width (erythropoietic stress pattern, possible mild anemia-like phenotype)
How to read the evidence
Evidence tier — overall strength of the evidence for the whole compound
- StrongWell established — backed by strong, consistent human research.
- ModerateSome genuine support, but mostly from small or lower-quality studies. Promising, not proven.
- PreliminaryEarly-stage evidence — a promising hypothesis, not an established effect yet.
- LimitedVery limited evidence — treat this as a hypothesis, not proof.
- InsufficientNot enough good evidence to draw conclusions yet.
Certainty — how sure we can be that the effect is real
- Very highVery sure — strong, consistent evidence
- HighFairly sure — consistent evidence from good studies
- MediumModerately sure — new studies could change this
- LowNot sure — little or mixed evidence
- Very lowVery unsure — almost no usable evidence
Source — where the data comes from
- Meta-analysisPooled analysis of many trials — the strongest evidence
- RCTRandomized controlled trial — a strong human study design
- ClinicalA human clinical study
- Reference knowledgeFrom general health-science or pharmacology references, not a study of this exact claim
- Animal researchStudied in animals, not humans
- Community reportsAggregated user reports — anecdotal signal, not evidence
- TheoreticalMechanism-based reasoning, not yet tested
Study grade — quality of each underlying study (A best, D weakest)
- AHigh-quality — strong, consistent human trials
- BGood — solid evidence with some limitations
- CModerate — limited, small, or mixed-quality studies
- DWeak — preliminary, indirect, or animal-only
Confidence — how strongly the sources back a finding
A 0–100 score from study quality and agreement
Most supplement evidence is graded C–D. Read it as preliminary signal, not proof.
Full write-up
What is it
RBC/Hemoglobin Decrease means a reduction in red blood cells or hemoglobin, the blood components measured when assessing oxygen-carrying capacity. It may be described as anemia when the decrease in hemoglobin is clinically interpreted that way. This outcome is distinct from changes in white blood cells or platelets. It has been reported in connection with interventions including CBD (Cannabidiol), Curcumin, Vitamin C, and Saffron Extract.
How interventions help
The interventions linked with RBC/Hemoglobin Decrease differ substantially in context. The outcome has been described as anemia or as measured decreases in red blood cells, hemoglobin, or hematocrit, rather than as one uniform response across all interventions. Prescription CBD (Cannabidiol) is associated particularly with antiseizure doses, while other findings involve supplements, Vitamin K1, or Ozone Therapy under more specific circumstances.
Exposure pattern appears important in some cases. Saffron Extract findings were reported over 2-3 weeks, with doses of 0.35-1.05 g/kg, 180 mg/kg, and 0.1-0.5 ml/kg. Zinc-related reports involved prolonged high-dose exposure, although the dose was not quantified. Vitamin K1-related hemolysis occurred in newborns, particularly premature infants receiving doses above those recommended, and Ozone Therapy has a particular concern for people with G6PD deficiency or inadequate screening.
The findings range from an isolated decrease in blood-cell counts to reports of anemia, hemolysis, and broader blood-count changes. The descriptions do not establish a consistent onset time, whether the effect persists after stopping, or a common duration across interventions. The populations studied are also not specified for most entries, so these findings should not be assumed to apply equally to every person, dose, or treatment setting.
Choosing guidance
Choosing among these options requires separating a reported association from a broadly applicable expectation. The evidence spans pharmacology references, clinical evidence, and a review rather than one consistent body of research. Clinical evidence appears for several options, while others rely on reference material or a review, so direct comparisons are limited. The health status of the studied populations is not specified, making it difficult to know how well the findings apply to a particular person.
Exposure context matters. The reported CBD finding concerns prescription cannabidiol, particularly antiseizure doses, rather than all possible uses. For Saffron Extract, the reviewed findings came from short exposure periods, whereas Zinc’s reports concerned prolonged high-dose exposure. Vitamin K1’s reported concern centers on newborns, especially premature infants, and Ozone Therapy’s relevance is tied to G6PD deficiency or inadequate screening. These contexts mean the options should not be treated as interchangeable.
People looking for an option with clinical evidence should still recognize that the findings include anemia, changes in blood-cell counts, or hemolysis, depending on the option and setting. The evidence does not establish how quickly changes appear, whether they persist, or which people are most susceptible. Particular care is warranted when considering use in newborns, prolonged high-dose exposure, or in the presence of G6PD deficiency.